Papers/PMID:36910362
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
African health sciences2022The record
4 findings · 1 compound · 4 endpoints · 4 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
4 findings
empagliflozin — no detected effect on alanine aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“In comparison with control group for non-alcoholic fatty liver disease, empagliflozin treatment shows no substantial impact on ALT (SMD=-0.09; 95% CI=-0.37 to 0.18; P=0.50; Figure 4), AST (SMD=-0.26; 95% CI=-0.53 to 0.02; P=0.07; Figure 5), LDL (SMD=-0.31; 95% CI=-0.74 to 0.11; P=0.15; Figure 6) or TG (SMD=-0.17; 95% CI=-0.54 to 0.19; P=0.35; Figure 7).”
Quoted verbatim from Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily
- Population
- Patients with non-alcoholic fatty liver disease, pooled across randomized trials of empagliflozin 10 mg daily versus placebo
Effect -0.09 standardised mean difference, 95% CI -0.37 to 0.18
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.2022PMID:36910362Permalink
empagliflozin — no detected effect on triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“In comparison with control group for non-alcoholic fatty liver disease, empagliflozin treatment shows no substantial impact on ALT (SMD=-0.09; 95% CI=-0.37 to 0.18; P=0.50; Figure 4), AST (SMD=-0.26; 95% CI=-0.53 to 0.02; P=0.07; Figure 5), LDL (SMD=-0.31; 95% CI=-0.74 to 0.11; P=0.15; Figure 6) or TG (SMD=-0.17; 95% CI=-0.54 to 0.19; P=0.35; Figure 7).”
Quoted verbatim from Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily
- Population
- Patients with non-alcoholic fatty liver disease, pooled across randomized trials of empagliflozin 10 mg daily versus placebo
Effect -0.17 standardised mean difference, 95% CI -0.54 to 0.19
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.2022PMID:36910362Permalink
empagliflozin — no detected effect on aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“In comparison with control group for non-alcoholic fatty liver disease, empagliflozin treatment shows no substantial impact on ALT (SMD=-0.09; 95% CI=-0.37 to 0.18; P=0.50; Figure 4), AST (SMD=-0.26; 95% CI=-0.53 to 0.02; P=0.07; Figure 5), LDL (SMD=-0.31; 95% CI=-0.74 to 0.11; P=0.15; Figure 6) or TG (SMD=-0.17; 95% CI=-0.54 to 0.19; P=0.35; Figure 7).”
Quoted verbatim from Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily
- Population
- Patients with non-alcoholic fatty liver disease, pooled across randomized trials of empagliflozin 10 mg daily versus placebo
Effect -0.26 standardised mean difference, 95% CI -0.53 to 0.02
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.2022PMID:36910362Permalink
empagliflozin — no detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“In comparison with control group for non-alcoholic fatty liver disease, empagliflozin treatment shows no substantial impact on ALT (SMD=-0.09; 95% CI=-0.37 to 0.18; P=0.50; Figure 4), AST (SMD=-0.26; 95% CI=-0.53 to 0.02; P=0.07; Figure 5), LDL (SMD=-0.31; 95% CI=-0.74 to 0.11; P=0.15; Figure 6) or TG (SMD=-0.17; 95% CI=-0.54 to 0.19; P=0.35; Figure 7).”
Quoted verbatim from Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily
- Population
- Patients with non-alcoholic fatty liver disease, pooled across randomized trials of empagliflozin 10 mg daily versus placebo
Effect -0.31 standardised mean difference, 95% CI -0.74 to 0.11
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.2022PMID:36910362Permalink